Imux stock forecast 2025 iMUX in 2025 may track biotech

IMUX in 2025 may track biotech innovation indices closely; upward momentum in sector rankings often correlates with improved institutional coverage and brokerage upgrades. It would appear that 32% of Immunic shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. BVF Partners L.P. is currently the company's largest shareholder with 9.9% of shares outstanding. With 8.8% and 8.1% of the shares outstanding respectively, Avidity Partners Management, L.P. and Soleus Capital Management, L.P. are the second and third largest shareholders. To see Spark’s full report on IMUX stock, click here . The current market sentiment around IMUX stock shows cautious optimism, with analysts eyeing 2025 as a potential rebound year if Phase 3 clinical trial data is favorable. Institutional investors are watching for cash burn rates and FDA updates that could shift valuation multiples.